Yale Cancer Center | Strategic Alliance Partners

Yale Cancer Center (YCC) is one of only 56 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

Latest from Yale Cancer Center

Dr Rimm on the Utility and Shortcomings of HER2 IHC Testing in Breast Cancer

November 18, 2024

Video

David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

November 14, 2024

Video

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

November 09, 2024

Article

David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.

Dr Rimm on Limitations With IHC Testing in HER2-Low and HER2-Ultralow Breast Cancer

October 23, 2024

Video

David Rimm, MD, discusses the current limitations of immunohistochemistry diagnostic kits for HER2-low and HER2-ultralow breast cancer.

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

October 17, 2024

Podcast

Dr Foss discusses the significance of the FDA approval of denileukin diftitox for patients with relapsed/refractory CTCL.

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

October 15, 2024

Article

Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

September 26, 2024

Podcast

Dr Shallis discusses the ELEMENT-MDS trial in MDS and the potential of intervening with luspatercept before patients become RBC transfusion dependent.

Clinical Scenario: Metastatic EBV-Positive NPC

September 25, 2024

Video

The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.

Dr Rimm on the Limitations of HER2 IHC Assays in Breast Cancer

September 19, 2024

Video

David Rimm, MD, PhD, discusses the limitations of current HER2 immunohistochemistry assays in breast cancer.

Clinical Scenario: Locally Recurrent NPC

September 18, 2024

Video

Shravan Kandula, MD, presents the case of a patient with locally recurrent nasopharyngeal carcinoma.

Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

September 18, 2024

Video

Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.

Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

September 11, 2024

Video

The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.

Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

September 11, 2024

Video

Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

September 04, 2024

Video

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

September 04, 2024

Video

Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.

Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management

August 29, 2024

Podcast

Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.

Value of PD-L1 Biomarker in NPC

August 28, 2024

Video

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

Overview of the JUPITER and POLARIS-2 Trials

August 28, 2024

Video

Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.

Dr Cecchini on Etrumadenant-Based Combinations in Previously Treated mCRC

August 26, 2024

Video

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.

Current Guidelines for Managing Nasopharyngeal Carcinoma

August 21, 2024

Video

Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.